<DOC>
	<DOCNO>NCT01147718</DOCNO>
	<brief_summary>This Phase I , open-label , sequential , single-center study evaluate pharmacokinetics digoxin coadministered albiglutide healthy adult subject .</brief_summary>
	<brief_title>A Drug Interaction Study Albiglutide Digoxin</brief_title>
	<detailed_description>This Phase I , open-label , sequential , single-center study evaluate pharmacokinetics digoxin coadministered albiglutide healthy adult subject . Subjects receive single dose digoxin Day 1 follow 5 weekly subcutaneously injected dos albiglutide second single dose digoxin Day 38 . To determine plasma pharmacokinetic parameter digoxin drug administration alone multiple dos albiglutide , blood sample collect dose digoxin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>healthy volunteer female subject must nonchildbearing potential clinically significant disease clinically significant abnormal laboratory value body mass index ( BMI ) &gt; /=18 kg â‰¤30 kg/m2 nonsmoker positive test result hepatitis B , hepatitis C human immunodeficiency virus female subject pregnant breastfeed history anaphylactic reaction drug history significant cardiovascular pulmonary dysfunction current chronic history liver disease history alcohol substance abuse history thyroid disease dysfunction history gastrointestinal surgery disease history pancreatitis history cholecystitis gallbladder disease previously receive GLP1 mimetic compound ( e.g. , exenatide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>albiglutide</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>digoxin</keyword>
</DOC>